These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35154589)

  • 1. Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder.
    Shahini N; Talaei A; Shalbafan M; Faridhosseini F; Ziaee M
    Basic Clin Neurosci; 2021; 12(4):489-498. PubMed ID: 35154589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
    Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
    Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
    Rutrick D; Stein DJ; Subramanian G; Smith B; Fava M; Hasler G; Cha JH; Gasparini F; Donchev T; Ocwieja M; Johns D; Gomez-Mancilla B
    Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Askari N; Moin M; Sanati M; Tajdini M; Hosseini SM; Modabbernia A; Najand B; Salimi S; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    CNS Drugs; 2012 Oct; 26(10):883-92. PubMed ID: 22873680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder.
    Vakili Y; Gharaee B; Habibi M
    Iran J Psychiatry Behav Sci; 2015 Jun; 9(2):e845. PubMed ID: 26288647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
    Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
    Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive-compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study.
    Westwell-Roper C; Best JR; Elbe D; MacFadden M; Baer S; Tucker L; Au A; Naqqash Z; Lin B; Lu C; Stewart SE
    BMJ Open; 2022 Jan; 12(1):e054296. PubMed ID: 35105633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.
    Yousefzadeh F; Sahebolzamani E; Sadri A; Mortezaei A; Aqamolaei A; Mortazavi SH; Shalbafan MR; Ghaffari S; Alikhani R; Mousavi SB; Naderi S; Shamabadi A; Jalilevand S; Akhondzadeh S
    Int Clin Psychopharmacol; 2020 Sep; 35(5):254-262. PubMed ID: 32541380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs).
    Nikzad F; Sadjadi SA; Mohammadpour AH; Ziaee M; Behdani F; Naghibi SM; Nejatifard SN; Ghanbari M; Akhondpour Manteghi A
    Iran J Psychiatry; 2021 Oct; 16(4):444-450. PubMed ID: 35082857
    [No Abstract]   [Full Text] [Related]  

  • 12. The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
    Yoosefee S; Amanat M; Salehi M; Mousavi SV; Behzadmanesh J; Safary V; Yoonesi A; Salehi B
    BMC Psychiatry; 2020 Nov; 20(1):570. PubMed ID: 33256659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary alpha-amylase and cortisol responsiveness following electrical stimulation stress in obsessive-compulsive disorder patients.
    Kawano A; Tanaka Y; Ishitobi Y; Maruyama Y; Ando T; Inoue A; Okamoto S; Imanaga J; Kanehisa M; Higuma H; Ninomiya T; Tsuru J; Akiyoshi J
    Psychiatry Res; 2013 Aug; 209(1):85-90. PubMed ID: 23266021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial.
    Shalbafan M; Mohammadinejad P; Shariat SV; Alavi K; Zeinoddini A; Salehi M; Askari N; Akhondzadeh S
    Pharmacopsychiatry; 2015 Jul; 48(4-5):136-40. PubMed ID: 25959196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
    Soltani F; Sayyah M; Feizy F; Malayeri A; Siahpoosh A; Motlagh I
    Hum Psychopharmacol; 2010 Aug; 25(6):509-13. PubMed ID: 20737524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy.
    Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W
    J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of symptom dimensions for obsessive compulsive disorder and obsessive compulsive-related disorders.
    Say Öcal D; Özdel K; Şafak Y; Kekilli Karnaz Y; Kısa C
    PLoS One; 2019; 14(7):e0218955. PubMed ID: 31276509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive transcranial magnetic stimulation (rTMS) augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD): a meta-analysis of randomized controlled trials.
    Ma ZR; Shi LJ
    Int J Clin Exp Med; 2014; 7(12):4897-905. PubMed ID: 25663986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive-Behavioral Therapy Versus Transcranial Direct Current Stimulation for Augmenting Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder Patients.
    Dadashi M; Yousefi Asl V; Morsali Y
    Basic Clin Neurosci; 2020; 11(1):111-120. PubMed ID: 32483481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options for OCD.
    Fineberg NA
    Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():24-30. PubMed ID: 24926869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.